Jon Moore is a molecular biologist and cell biologist with 22 years of scientific leadership experience in industry, across oncology, gene editing and company creation.

Jon spent six years at gene editing tools and services company, Horizon Discovery (now part of Revitty) serving as its CSO from 2014 to 2018. He subsequently joined Advent Life Sciences as an Operating Partner where he co-founded the cancer immunotherapeutics start-up Epitopea, and the remyelination start-up Pheno Therapeutics, serving both companies as their first CEO.

Earlier in his career, Jon gained extensive postdoctoral experience with Nobel Prize winner Tim Hunt at Cancer Research UK and current MIT president, Sally Kornbluth at Duke University. He holds a PhD from the University of Newcastle upon Tyne.